Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
via Google News
The Latest on: Cancer
- Scientists help immune system find hidden cancer cellson October 14, 2019 at 9:53 am
Cancer cells are masters at avoiding detection, but a new system can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might ...
- Sun-Wise Campaigns May Have Reduced Skin Cancer Rateson October 14, 2019 at 9:35 am
Suzanne Dobbinson, PhD, senior research fellow at Cancer Council Victoria in Melbourne, Australia, and colleagues found that, compared with the year before SunSmart was launched, there were marked ...
- Toddler dancing to celebrate 11 months cancer-free goes viralon October 14, 2019 at 8:29 am
An adorable video of a New Jersey father and son letting loose to celebrate the tot’s 11th month of being cancer-free has gone viral after it was shared on Instagram. Kenny “Clutch” Thomas and his son ...
- Researchers discover a new way to improve the assessment of prostate cancer aggressivenesson October 14, 2019 at 6:29 am
This technique could complement traditional assessment methods and may help clinicians to make more informed personalized treatment decisions for men with prostate cancer. In the long run, it may ...
- Ex-FDA chief Scott Gottlieb says he is 'skeptical' that vaping nicotine causes lung canceron October 14, 2019 at 5:43 am
"I'm skeptical that nicotine causes cancer," Gottlieb says. "It might be a tumor promoter," he acknowledges. "But it doesn't cause cancer." The former FDA commissioner was reacting to a New York ...
- Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cellson October 14, 2019 at 2:41 am
Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that ...
- Silencing of Glutathione S-Transferase Pi Inhibits Cancer Cell Growth via Oxidative Stress Induced by Mitochondria Dysfunctionon October 14, 2019 at 2:12 am
Antitumor drug development based on the concept of intervening in the antioxidant system of cancer cells has been gaining increased interest. In this study, we propose a promising strategy for cancer ...
- Staying on Guard Against Skin Canceron October 14, 2019 at 2:00 am
The report that came back on New Year’s Eve 2013 could not have been more shocking: a very rare and aggressive form of skin cancer called Merkel cell carcinoma. It’s a diagnosis made only 2,500 times ...
- She claimed her son had cancer and subjected him to 13 surgeries. He wasn’t actually sick.on October 13, 2019 at 1:39 pm
“She would always say, ‘Something’s wrong. He has this. He has that.’ ” Over the years, Christopher’s mother would claim he had cancer, a genetic disorder and seizures, among other ailments. An ...
- Ryan Murphy announces young son is cancer-freeon October 12, 2019 at 9:00 am
American Horror Story' creator Ryan Murphy's five-year-old son is cancer-free. The 53-year-old screenwriter-and-director and his husband David Miller's little boy Ford Theodore Miller Murphy was ...
via Bing News